Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off To A Good Start

By Zacks Investment ResearchStock MarketsMay 14, 2019 02:36AM ET
www.investing.com/analysis/catalyst-cprx-q1-loss-narrows-firdapse-off-to-a-good-start-200421346
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off To A Good Start
By Zacks Investment Research   |  May 14, 2019 02:36AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported a loss of 1 cent per share in the first quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 13 cents and the year-ago loss of 6 cents.

The company’s revenues of $12.4 million in the first quarter of 2019 surpassed the Zacks Consensus Estimate of $1 million. The company did not record any revenue in the year-ago quarter. Revenues came entirely from Firdapse, the company’s first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The drug was launched in the United States in January 2019 after receiving the FDA approval in November 2018.

So far this year, Catalyst’s shares have increased 64.6% year to date compared with the industry’s growth of 6.0%.

Quarter in Detail

The company said that Firdapse had a strong start. As of May 9, 2019, the drug has been prescribed to409 unique LEMS patients. This included 81 patients previously naive to any form of amifampridine.

Research and development (R&D) expenses were $3.3 million, almost the same as $3.2 million in the year-ago quarter. The R&D costs included expenses in medical, regulatory affairs and quality assurance programs as well as expenses from the company’s Firdapse clinical trials, studies and Expanded Access Program.

General and administrative expenses totaled $8.4 million, surging 228.7% from the year-ago quarter. The increase is attributable to higherselling expenses, including the cost of the sales force and supporting personnel, product launch expenses, and market access and research expenses. The company expects selling, general and administrative expenses to increase in 2019, as it continues to build the infrastructure, and invest in commercial and patient programs to support Firdapse sales activities in 2019.

Pipeline Update

Catalyst is also working on developing Firdapse for additional indications. The company is currently conducting phase III studies, evaluating the drug for the treatment of congenital myasthenic syndromes (“CMS”) and anti-MuSK -antibody positive myasthenia gravis (MuSK-MG).

The company expects to report top-line results from the phase III MuSK-MG and CMS studies in the second half of 2019.

Catalyst is conducting a proof-of-concept study, evaluating Firdapse as a symptomatic treatment for patients with SMA type III. The company expects to report top-line results from the study in the first half of 2020.

Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise

Catalyst Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Catalyst Pharmaceuticals, Inc. Quote

Zacks Rank & Stocks to Consider

Catalyst currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks worth considering are BioSpecifics Technologies Corp. (NASDAQ:BSTC) , Eisai Co., Ltd. (OTC:ESALY) and Recro Pharma, Inc. (NASDAQ:REPH) . All of them carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

BioSpecifics’ earnings per share estimates have increased from $2.78 to $3.01 for 2019 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 14.21%.

Eisai’s earnings per share estimates have increased from $1.91 to $1.95 for 2019 and from $1.93 to $2.02 for 2020 in the past 60 days.

Recro Pharma’s loss per share estimates have narrowed from $3.40 to $1.94 for 2019 and from $1.51 to 56 cents for 2020 over the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average of 41.88%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



BioSpecifics Technologies Corp (BSTC): Free Stock Analysis Report

Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report

Recro Pharma, Inc. (REPH): Free Stock Analysis Report

Eisai Co. (ESALY): Free Stock Analysis Report

Original post

Zacks Investment Research
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off To A Good Start
 

Related Articles

Anna Coulling
Will Santa Rally Help Tesla? By Anna Coulling - Dec 01, 2021 5

It's time to check in on Tesla (NASDAQ:TSLA) as the markets recover from virus volatility and head into the pre-Christmas rally. At least that’s the theory: With Santa’s workshop...

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off To A Good Start

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email